Empagliflozin/metformin

Empagliflozin/metformin
Combination of
Empagliflozin	SGLT2 inhibitor
Metformin Hydrochloride	Anti-diabetic biguanide
Clinical data
Trade names	Synjardy
License data	EU EMA: by INN; US DailyMed: Synjardy; US FDA: Synjardy;
Pregnancy; category	AU: D [1]; US: N (Not classified yet) [1];
Routes of; administration	By mouth
ATC code	A10BD20 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) [2]; US: ℞-only ;
Identifiers
CAS Number	864070-44-0 ; 657-24-9 ;
PubChem CID	85364160;
UNII	HDC1R2M35U; 9100L32L2N ;
KEGG	D10752;
ChEBI	CHEBI:90875;
Chemical and physical data
Formula	C27H39Cl2N5O7
Molar mass	616.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C(=N)N=C(N)N.COC1C(C(C(C(O1)C2=CC(=C(C=C2)Cl)CC3=CC=C(C=C3)OC4CCOC4)O)O)O.Cl;
	InChI InChI=1S/C23H27ClO7.C4H11N5.ClH/c1-28-23-21(27)19(25)20(26)22(31-23)14-4-7-18(24)15(11-14)10-13-2-5-16(6-3-13)30-17-8-9-29-12-17;1-9(2)4(7)8-3(5)6;/h2-7,11,17,19-23,25-27H,8-10,12H2,1H3;1-2H3,(H5,5,6,7,8);1H/t17-,19+,20+,21-,22-,23-;;/m0../s1; Key:YBRWIMHXUHRVDV-ZBYKXHQASA-N;

Empagliflozin/metformin, sold under the brand name Synjardy, is a combination medication used to treat type 2 diabetes. It is composed of empagliflozin and metformin hydrochloride.[3]

History

Empagliflozin/metformin hydrochloride was approved for use in the United States in August 2015.[3][4] The extended release version was approved for use in the United States in December 2016.[5][6]

References

"Empagliflozin / metformin Use During Pregnancy". Drugs.com. 10 September 2019. Retrieved 11 February 2020.
"Synjardy film coated tablets - Summary of Product Characteristics (SmPC)". (emc). 23 October 2019. Retrieved 10 February 2020.
"Synjardy (empagliflozin and metformin hydrochloride) Tablets". U.S. Food and Drug Administration (FDA). 4 August 2016. Retrieved 10 February 2020.
"Synjardy: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.
"Synjardy XR (empagliflozin and metformin hydrochloride extended-release) Tablets". U.S. Food and Drug Administration (FDA). 26 October 2017. Retrieved 10 February 2020.
"Synjardy XR: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 11 February 2020.

External links

"Empagliflozin mixture with metformin hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
"Empagliflozin". MedlinePlus.
"Metformin". MedlinePlus.
"Synjardy EPAR". European Medicines Agency (EMA).
"Synjardy XR- empagliflozin, metformin hydrochloride tablet, extended release". DailyMed.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Drugs.com_pregnancy-1] "Empagliflozin / metformin Use During Pregnancy". Drugs.com. 10 September 2019. Retrieved 11 February 2020.

[2] "Synjardy film coated tablets - Summary of Product Characteristics (SmPC)". (emc). 23 October 2019. Retrieved 10 February 2020.

[FDA_Approval-3] "Synjardy (empagliflozin and metformin hydrochloride) Tablets". U.S. Food and Drug Administration (FDA). 4 August 2016. Retrieved 10 February 2020.

[4] "Synjardy: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.

[5] "Synjardy XR (empagliflozin and metformin hydrochloride extended-release) Tablets". U.S. Food and Drug Administration (FDA). 26 October 2017. Retrieved 10 February 2020.

[6] "Synjardy XR: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 11 February 2020.